Comparative Pharmacology
Head-to-head clinical analysis: TRAVATAN versus TRYVIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVATAN versus TRYVIO.
TRAVATAN vs TRYVIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective FP prostanoid receptor agonist; increases uveoscleral outflow of aqueous humor by relaxing the ciliary muscle and remodeling the extracellular matrix in the ciliary body.
Tryvio (vobadimustat) is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes HIF-α, leading to increased erythropoietin production and stimulation of erythropoiesis.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
Adults: 0.25 mg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 45 minutes for travoprost acid (active metabolite). Clinical context: due to rapid systemic clearance, ocular hypotensive effect persists for 24 hours from corneal tissue binding.
Terminal elimination half-life 44-60 hours in healthy adults; prolonged in hepatic impairment (up to 120 hours).
Renal (primarily as metabolites): ~70%; Fecal: ~25%; Unchanged drug in urine: <1%
Primarily hepatic metabolism; 90% as inactive metabolites in feces, <5% unchanged in urine; <5% in bile.
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog